A Phase IB study of Durvalumab with or without Tremelimumab and Platinum-Doublet Chemotherapy in Advanced Solid Tumours: Canadian Cancer Trials Group Study IND226

Immune checkpoint inhibitors are now established therapies across several cancers including melanoma, renal cell, bladder and non-small cell lung cancer (NSCLC) [1 –4]. Preclinical data and emerging clinical data suggest that the combination of antibodies against programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may be a more promising approach because of non-redundant pathway blockade and synergy which in turn, may r esult in more durable anti-tumour activity [5–8].

Source: Lung Cancer - February 27, 2020 Category: Cancer & Oncology Authors: Rosalyn A. Juergens, Desiree Hao, Peter M. Ellis, Dongsheng Tu, Mihaela Mates, Christian Kollmannsberger, Penelope A. Bradbury, Moustapha Tehfe, Paul Wheatley-Price, Andrew Robinson, Gwyn Bebb, Janessa Laskin, John Goffin, John Hilton, Anna Tomiak, Sebast Tags: Review Source Type: research